It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neuroligin-2 (Nlgn2) is a key synaptic adhesion protein at virtually all GABAergic synapses, which recruits GABAARs by promoting assembly of the postsynaptic gephyrin scaffold. Intriguingly, loss of Nlgn2 differentially affects subsets of GABAergic synapses, indicating that synapse-specific interactors and redundancies define its function, but the nature of these interactions remain poorly understood. Here we investigated how Nlgn2 function in hippocampal area CA1 is modulated by two proposed interaction partners, MDGA1 and MDGA2. We show that loss of MDGA1 expression, but not heterozygous deletion of MDGA2, ameliorates the abnormal cytosolic gephyrin aggregation, the reduction in inhibitory synaptic transmission and the exacerbated anxiety-related behaviour characterizing Nlgn2 knockout (KO) mice. Additionally, combined Nlgn2 and MDGA1 deletion causes an exacerbated layer-specific loss of gephyrin puncta. Given that both Nlgn2 and the MDGA1 have been correlated with many psychiatric disorders, our data support the notion that cytosolic gephyrin aggregation may represent an interesting target for novel therapeutic strategies.
Analysis of inhibitory synapses in mouse hippocampus uncovers functional interactions between postsynaptic organizer proteins Neuroligin-2 and MDGA1 in regulating gephyrin aggregation, GABAergic synaptic transmission, and behavior.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Max Planck Institute for Multidisciplinary Sciences, Department of Molecular Neurobiology, Göttingen, Germany; University Medical Center of the Johannes Gutenberg-University Mainz, Institute of Anatomy, Mainz, Germany (GRID:grid.410607.4)
2 Max Planck Institute for Multidisciplinary Sciences, Department of Molecular Neurobiology, Göttingen, Germany (GRID:grid.410607.4); Georg-August-University Göttingen, Göttingen Graduate School for Neurosciences, Biophysics, and Molecular Biosciences (GGNB), Göttingen, Germany (GRID:grid.7450.6) (ISNI:0000 0001 2364 4210)
3 University Medical Center of the Johannes Gutenberg-University Mainz, Institute of Anatomy, Mainz, Germany (GRID:grid.410607.4); University Medical Center of the Johannes Gutenberg-University Mainz, Focus Program Translational Neurosciences (FTN), Mainz, Germany (GRID:grid.410607.4)
4 Max Planck Institute for Multidisciplinary Sciences, Department of Molecular Neurobiology, Göttingen, Germany (GRID:grid.410607.4)
5 Max Planck Institute for Multidisciplinary Sciences, Department of Molecular Neurobiology, Göttingen, Germany (GRID:grid.410607.4); and Bellvitge Biomedical Research Institute (IDIBELL), Department of Pathology and Experimental Therapy, Institute of Neurosciences, University of Barcelona, Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257)
6 Max Planck Institute for Multidisciplinary Sciences, Department of Molecular Neurobiology, Göttingen, Germany (GRID:grid.418284.3)
7 Max Planck Institute for Multidisciplinary Sciences, Department of Molecular Neurobiology, Göttingen, Germany (GRID:grid.418284.3); Universidad de Antofagasta, Departamento Biomedico, Facultad de Ciencias de la Salud, Antofagasta, Chile (GRID:grid.412882.5) (ISNI:0000 0001 0494 535X)
8 University Medical Center of the Georg-August-University Göttingen Mainz, Department of Psychiatry and Psychotherapy, Göttingen, Germany (GRID:grid.411984.1) (ISNI:0000 0001 0482 5331); German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426); University of Aveiro, Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, Aveiro, Portugal (GRID:grid.7311.4) (ISNI:0000 0001 2323 6065)
9 Max Planck Institute for Multidisciplinary Sciences, Department of Molecular Neurobiology, Göttingen, Germany (GRID:grid.7311.4)
10 Max Planck Institute for Multidisciplinary Sciences, Department of Molecular Neurobiology, Göttingen, Germany (GRID:grid.7311.4); University Medical Center of the Johannes Gutenberg-University Mainz, Institute of Anatomy, Mainz, Germany (GRID:grid.410607.4); University Medical Center of the Johannes Gutenberg-University Mainz, Focus Program Translational Neurosciences (FTN), Mainz, Germany (GRID:grid.410607.4); University Medical Center of the Georg-August-University Göttingen Mainz, Department of Psychiatry and Psychotherapy, Göttingen, Germany (GRID:grid.411984.1) (ISNI:0000 0001 0482 5331)